4 Healthcare Stock Stories Closing Out June Trading

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Sanofi-Aventis (NYSE: SNY): Closing price $51.51

The Sanofi company Genzyme said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of Lemtrada (alemtuzumab) for the treatment of adult patients suffering from relapsing remitting multiple sclerosis, with active disease defined by clinical or imaging features. Beyond that, the Committee released a positive opinion on new active substance designation for Aubagio (teriflunomide). Earlier in 2013, the Committee issued a positive opinion recommending the clearance of Aubagio for the treatment of adult patients with relapsing remitting MS.

Are these stocks a buy or sell? Let us help you decide. SNY

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business